What is MetLife's EMEA — goodwill?

MetLife (MET) reported EMEA — goodwill of $927M in Q4 2025.

How has MetLife's EMEA — goodwill changed year-over-year?

MetLife's EMEA — goodwill increased by 3.6% year-over-year, from $895M to $927M.

What does EMEA — goodwill mean?

This is the net carrying value of goodwill for the EMEA segment, representing the excess of the purchase price over the fair value of net assets acquired. It serves as an intangible asset on the balance sheet subject to periodic impairment testing.

MetLife MET EMEA — Goodwill

Similar metrics at other companies

TFX

TFXEMEA — Goodwill

$659.05M+36.9%

TTEMEA — Goodwill

$938.5M+6.9%

CWKEMEA — Goodwill

$343.7M+4.2%

KWREMEA — Goodwill

$0-100%

ADNTEMEA — Goodwill

$0—

KFYEMEA — Goodwill

$47M+0.8%

Other financials

Income statement

See full

Revenue$19.1B+2.7%

Net income$1.2B+25.4%

EPS (diluted)$1.74+35.9%

Balance sheet

See full

Cash & equivalents$22.7B+6.4%

Total debt$14.8B-1.5%

Total equity$27.3B-0.6%

Total assets$743.21B+8.0%

Cash flow

See full

Operating cash flow$2.7B-37.0%

Valuation

See full

Market cap$54.45B+2.4%

Enterprise value$46.62B-0.7%

P/E15.1×+3.2×

P/S0.7×0.0×

Profitability

See full

Net margin4.7%-1.5pp

Returns & leverage

See full

Return on equity13.2%-2.9pp

Debt / equity0.5×0.0×

Where this comes from

Reported directly by MetLife in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: MetLife’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about MetLife's emea — goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MetLife's EMEA — goodwill?: MetLife (MET) reported EMEA — goodwill of $927M in Q4 2025.
How has MetLife's EMEA — goodwill changed year-over-year?: MetLife's EMEA — goodwill increased by 3.6% year-over-year, from $895M to $927M.
What does EMEA — goodwill mean?: This is the net carrying value of goodwill for the EMEA segment, representing the excess of the purchase price over the fair value of net assets acquired. It serves as an intangible asset on the balance sheet subject to periodic impairment testing.